

Samvel B Gasparyan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4692351/publications.pdf>

Version: 2024-02-01

9
papers

283
citations

1306789

7
h-index

1588620

8
g-index

9
all docs

9
docs citations

9
times ranked

359
citing authors

#	ARTICLE	IF	CITATIONS
1	Dapagliflozin in patients with COVID-19: mind the kidneys – Authors' reply. Lancet Diabetes and Endocrinology, 2022, 10, 98-99.	5.5	0
2	Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 643-654.	2.2	10
3	Comments on “Sample size formula for a win ratio endpoint” by R. X. Yu and J. Ganju. Statistics in Medicine, 2022, 41, 2688-2690.	0.8	3
4	Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial. Therapeutic Innovation and Regulatory Science, 2022, 56, 785-794.	0.8	9
5	Adjusted win ratio with stratification: Calculation methods and interpretation. Statistical Methods in Medical Research, 2021, 30, 580-611.	0.7	29
6	Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study. Diabetes, Obesity and Metabolism, 2021, 23, 886-896.	2.2	40
7	Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. Circulation, 2021, 143, 1962-1972.	1.6	35
8	Power and sample size calculation for the win odds test: application to an ordinal endpoint in COVID-19 trials. Journal of Biopharmaceutical Statistics, 2021, 31, 765-787.	0.4	12
9	Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes and Endocrinology, 2021, 9, 586-594.	5.5	145